Table 1 Demographic and disease characteristics of the participants.
Latent variables | Observed variables [range], adopted response | Data available, n (%) | Applicable sample, n (%) | Mean (SD) | Median (25%, 75% IQR) | ||||
|---|---|---|---|---|---|---|---|---|---|
Personal factors | |||||||||
p1 | Age, y | 477 | (100.0) | 65.4 | (12.4) | 67 | (57, 74) | ||
p2 | Sex, male | 475 | (99.6) | 261 | (54.9) | ||||
p3 | Body mass index, kg/m2 | 465 | (97.5) | 21.4 | (3.3) | 21.2 | (19.1, 23.7) | ||
p4 | Educational background, post-secondary | 474 | (99.4) | 291 | (61.0) | ||||
Medical factors | |||||||||
m1 | Disease type, complex | 466 | (97.7) | 330 | (70.8) | ||||
m2 | Disease duration, years | 448 | (93.9) | 13.8 | (11.0) | 10.8 | (6.0, 18.2) | ||
m3 | Number of common complications | 402 | (84.3) | 0.6 | (0.8) | 0 | (0, 1) | ||
m4 | Number of disease-related complications | 402 | (84.3) | 0.5 | (0.8) | 0 | (0, 1) | ||
m5 | Number of medications | 467 | (97.9) | 4.4 | (3.5) | 4 | (2, 6) | ||
m6 | Drugs for cerebellar symptoms, yes | 435 | (91.2) | 284 | (65.3) | ||||
m7 | Drugs for Parkinsonism, yes | 434 | (91.0) | 76 | (17.5) | ||||
m8 | History of falls within the past year, ≥ 1 | 458 | (96.0) | 365 | (79.7) | ||||
Environmental factors | |||||||||
s1 | Type of residence, home | 475 | (99.6) | 444 | (93.5) | ||||
s2 | Environmental improvement, yes | 467 | (97.9) | 367 | (78.6) | ||||
s3 | Cohabitation, yes | 457 | (95.8) | 399 | (87.3) | ||||
s4 | Caregiver support, yes | 436 | (91.4) | 384 | (88.1) | ||||
s5 | Work, yes | 447 | (93.7) | 104 | (23.3) | ||||
s6 | Need for social support [0–10] | 459 | (96.2) | 7.6 | (2.5) | 8 | (6, 10) | ||
s7 | Satisfaction with social support [0–10] | 456 | (95.6) | 5.6 | (2.3) | 5 | (5, 7) | ||
Impairments | |||||||||
i1 | Ataxia [0–3], ≥ 1 | 471 | (98.7) | 468 | (99.4) | 2.4 | (0.8) | 3 | (2, 3) |
i2 | Weakness [0–3], ≥ 1 | 473 | (99.2) | 419 | (88.6) | 1.8 | (1.0) | 2 | (1, 3) |
i3 | Rigidity [0–3], ≥ 1 | 467 | (97.9) | 335 | (71.7) | 1.3 | (1.1) | 1 | (0, 2) |
i4 | Spasticity [0–3], ≥ 1 | 462 | (96.9) | 294 | (63.6) | 1.2 | (1.1) | 1 | (0, 2) |
i5 | Imbalance [0–3], ≥ 1 | 470 | (98.5) | 462 | (98.3) | 2.5 | (0.8) | 3 | (2, 3) |
i6 | Malalignment [0–3], ≥ 1 | 466 | (97.7) | 290 | (62.2) | 1.1 | (1.1) | 1 | (0, 2) |
i7 | Fatigue [0–3], ≥ 1 | 464 | (97.3) | 388 | (83.6) | 1.6 | (1.0) | 2 | (1, 2) |
i8 | Pain [0–3], ≥ 1 | 452 | (94.8) | 193 | (42.7) | 0.8 | (1.0) | 0 | (0, 2) |
i9 | Numbness [0–3], ≥ 1 | 446 | (93.5) | 150 | (33.6) | 0.6 | (0.9) | 0 | (0, 1) |
i10 | Sensory disturbances [0–3], ≥ 1 | 467 | (97.9) | 268 | (57.4) | 1.0 | (1.0) | 1 | (0, 2) |
i11 | Tremor [0–3], ≥ 1 | 468 | (98.1) | 289 | (61.8) | 1.1 | (1.1) | 1 | (0, 2) |
i12 | Involuntary movements [0–3], ≥ 1 | 454 | (95.2) | 235 | (51.8) | 0.9 | (1.0) | 1 | (0, 1) |
i13 | Orthostatic hypotension [0–3], ≥ 1 | 469 | (98.3) | 186 | (39.7) | 0.7 | (1.0) | 0 | (0, 1) |
i14 | Poor sleep [0–3], ≥ 1 | 468 | (98.1) | 228 | (48.7) | 0.8 | (1.0) | 0 | (0, 1) |
i15 | Respiratory disorder [0–3], ≥ 1 | 466 | (97.7) | 175 | (37.6) | 0.6 | (0.9) | 0 | (0, 1) |
i16 | Speech dysarthria [0–3], ≥ 1 | 473 | (99.2) | 437 | (92.4) | 2.0 | (1.0) | 2 | (1, 3) |
i17 | Dysphagia [0–3], ≥ 1 | 474 | (99.4) | 389 | (82.1) | 1.5 | (1.0) | 1 | (1, 2) |
i18 | Visual impairment [0–3], ≥ 1 | 472 | (99.0) | 314 | (66.5) | 1.2 | (1.1) | 1 | (0, 2) |
i19 | Urinary impairment [0–3], ≥ 1 | 472 | (99.0) | 294 | (62.3) | 1.3 | (1.2) | 1 | (0, 2) |
i20 | Bowel impairment [0–3], ≥ 1 | 476 | (99.8) | 282 | (59.2) | 1.2 | (1.2) | 1 | (0, 2) |
i21 | Cognitive impairment [0–3], ≥ 1 | 475 | (99.6) | 210 | (44.2) | 0.6 | (0.8) | 0 | (0, 1) |
i22 | PHQ-2 score [0–6], ≥ 1 | 458 | (96.0) | 286 | (62.4) | 1.8 | (1.8) | 1 | (0, 3) |
Activity limitations | |||||||||
a1 | mRS score [0–5], ≤ 2 (= independence) | 461 | (96.6) | 110 | (23.9) | 3.4 | (1.1) | 4 | (3, 4) |
a2 | Indoor mobility1,2,3,4,5, ≥ 4 (= ambulatory) | 461 | (96.6) | 165 | (35.8) | 3.6 | 1.4 | 4 | (2, 5) |
a3 | Outdoor mobility1,2,3,4,5, ≥ 4 (= ambulatory) | 469 | (98.3) | 149 | (31.8) | 2.8 | 1.3 | 3 | (2, 4) |
a4 | BI [0–100] | 474 | (99.4) | 70.1 | (36.6) | 90 | (45, 100) | ||
a5 | LSA score [0–120] | 475 | (99.6) | 36.7 | (28.4) | 30 | (17, 48.5) | ||
Quantity of rehabilitation | |||||||||
r1 | Types of rehabilitation implemented, ≥ 1 | 477 | (100.0) | 368 | (77.1) | ||||
r2 | Types of therapy, maximum of 3 | 477 | (100.0) | 1.3 | (1.0) | 1 | (0, 2) | ||
r3 | Total rehabilitation time, min/month | 477 | (100.0) | 543.4 | (609.5) | 320 | (160, 720) | ||
r4 | Duration of rehabilitation, months | 476 | (99.8) | 49.4 | (64.0) | 30 | (2, 71.5) | ||
r5 | Types of rehabilitation program | 477 | (100.0) | 5.9 | (4.4) | 5 | (2.5, 9) | ||
r6 | Self-rehabilitation, yes | 450 | (94.3) | 324 | (72.0) | ||||
Quality of rehabilitation | 368 | (77.1) | |||||||
r7 | Effects of rehabilitation [0–10] | 356 | (96.7) | 6.4 | (2.4) | 6 | (5, 8) | ||
r8 | Self-efficacy of rehabilitation [0–10] | 355 | (96.5) | 6.1 | (2.5) | 6 | (5, 8) | ||
r9 | Satisfaction with rehabilitation [0–10] | 354 | (96.2) | 6.5 | (2.4) | 7 | (5, 8) | ||
r10 | Motivation for rehabilitation [0–10] | 354 | (96.2) | 7.2 | (2.4) | 8 | (6, 9) | ||
Quality of life | |||||||||
q1 | EQ index [0.00–1.00] | 456 | (95.6) | 0.49 | (0.23) | 0.51 | (0.31, 0.66) | ||
q2 | EQ-VAS [0–100] | 440 | (92.2) | 57.9 | (23.9) | 60 | (45, 78.5) | ||
q3 | Life satisfaction score [0–10] | 456 | (95.6) | 5.1 | (2.3) | 5 | (4, 7) | ||
